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Tumor vascularization is an essential modulator of early tumor growth, progression, and therapeutic outcome. Although
antiangiogenic treatments appear promising, intrinsic and acquired tumor resistance contributes to treatment failure. Clinical
inhibition of the molecular chaperone heat shock protein 90 (Hsp90) provides an opportunity to target multiple aspects of this
signaling resiliency, which may elicit more robust and enduring tumor repression relative to eﬀects elicited by speciﬁcally targeted
agents. This review highlights several primary eﬀectors of angiogenesis modulated by Hsp90 and describes the clinical challenges
posed by the redundant circuitry of these pathways. The four main topics addressed include (1) Hsp90-mediated regulation
of HIF/VEGF signaling, (2) chaperone-dependent regulation of HIF-independent VEGF-mediated angiogenesis, (3) Hsp90-
dependent targeting of key proangiogenic receptor tyrosine kinases and modulation of drug resistance, and (4) consideration
of factors such as tumor microenvironment that pose several challenges for the clinical eﬃcacy of anti-angiogenic therapy and
Hsp90-targeted strategies.
1.Introduction
The concept of antiangiogenic targeting as a means to
suppress malignancy came to the forefront of cancer thera-
peuticsintheearly1970s,baseduponthepioneeringworkof
Folkman [1]. Tumor vascularization is a critical component
ofcancerprogression,malignancy,andmetastasis.Asrapidly
dividingcancercellsreachacriticaltumorsize,themassout-
grows its supply of blood, oxygen, and nutrients. Continued
tumor growth depends upon the ability of microenviron-
mental stressors to trigger the activation of a complex and
intricately interconnected signaling network that culminates
in vascularization of the growing tumor. This activation
process is essential for initiation of the “angiogenic switch,” a
rate limiting event of tumor progression. Subsequent tumor
vascularization culminates in either enhanced angiogenesis,
the sprouting from local vessels, or vasculogenesis, the
formation of neovessels through bone marrow-derived cell
(BMDC) recruitment. Realization that the angiogenic switch
may represent a universal Achilles heel for all tumors,
coupled with elucidation of druggable targets within this
network, has invigorated the ﬁeld of antiangiogenic therapy,
resulting in a rich pipeline of therapeutic compounds [2].
2.Emergence of Hsp90 Inhibitorsas
Antiangiogenic Chemotherapeutic Agents
Although a number of antiangiogenic therapies are presently
in clinical use, the vast majority of these target a speciﬁc
molecule or receptor family [3]. Despite a relatively high
degree of speciﬁcity, the clinical eﬃcacy of these therapies as
curative agents remains poor. Though initial responsiveness
may occur, the ultimate outcome is treatment resistance
due to drug-dependent selection of intrinsic and adaptive
resistance mechanisms. Therefore, attention has turned to
chemotherapeutics targeting heat shock protein 90 (Hsp90),
which simultaneously target multiple proangiogenic regu-
lators, and may thus weaken the signaling resiliency char-
acteristic of tumor cells. The prototypic Hsp90 inhibitor
geldanamycin (GA) demonstrates potent antiangiogenic and
antitumorigenic properties [4, 5]. At the molecular level,
Hsp90 plays a critical role in the proper folding of its2 Journal of Oncology
client or substrate proteins [6] and also serves as a scaﬀold
protein to facilitate interactions between several receptor
tyrosine kinases (RTKs) and their substrates. Therefore,
Hsp90 inhibitors are unique as antiangiogenic agents in
that they regulate the activity of hundreds of proteins,
many of which support cancer growth [7–9]. In addition,
Hsp90 expression is increased in many cancers, allowing
sustainedactivationofcancer-speciﬁcdysregulatedpathways
and the buﬀering of stress conditions characteristic of the
tumor microenvironment [10]. As a result, the evaluation
of emergent Hsp90 inhibitors is a current focus of drug
discovery eﬀorts across multiple cancers [8, 9, 11].
The ﬁrst discovered Hsp90 inhibitor, GA, is a nat-
urally occurring benzoquinone ansamycin [12] that acts
as a nucleotide mimetic to inhibit ATP-dependent Hsp90
chaperone activity. Although useful as a research tool, the
pharmacological liabilities of GA prohibit its clinical use [13]
leading to the development of subsequent generations of
Hsp90 inhibitors including the GA analog 17-(allylamino)-
17-demethoxygeldanamycin (17-AAG) and its water sol-
uble version 17-dimethylaminoethylamino-17-demethoxy-
geldanamycin (17-DMAG), both of which are being eval-
uated in multiple Phase I, II, and III clinical trials [14–
16]. Alternatively, Hsp90 function and angiogenesis may be
impaired by histone deacetylase (HDAC) inhibitors, that act
upon the chaperone in a manner distinct from compounds
thattarget its N-terminal ATP-binding pocket. Currently, the
HDAC inhibitor LBH589/Panobinostat is under evaluation
in Phase I and II trials [17]. The development of Hsp90
inhibitors, although in its infancy a decade ago, is now
coming to the forefront of cancer therapy, with over 13 new
entities being tested in a variety of preclinical models and
human trials [18]. The antiangiogenic and antitumor eﬀects
of these agents will be discussed herein.
2.1. Rationale for Hsp90-Dependent Targeting of HIF.
Hypoxia inducible factor (HIF) is perhaps one of the most
potent proangiogenic proteins regulated by Hsp90. Of the
three known HIF isoforms, HIF-1 and HIF-2 contribute
to cancer progression and their widespread overexpression
in cancers correlates with increased mortality [19]. During
tumor growth, HIF transactivates genes to favor survival
under conditions of decreasing oxygen and nutrient avail-
ability [20]. A substantial number of these genes, such as
vascular endothelial growth factor (VEGF) (Figure 1), fall
within the category of proangiogenic cytokines, which col-
lectively tip the scales in favor of angiogenesis and neovascu-
larization as part of the angiogenic switch. Activation of this
HIF-driven angiogenic switch releases growth constraints
uponthetumorandsustainssubsequentprogression.Tumor
cells have evolved multiple mechanisms for upregulating
HIF expression and activity, most commonly via modulation
of the HIF-α subunit, normally a tightly regulated labile
protein subject to proteasomal degradation [21–23]. In
general, these mechanisms block oxygen-dependent prolyl
hydroxylase (PHD) enzymes from tagging HIF for degra-
dation, ultimately preventing its proteasomal degradation
via the von Hippel Lindau (VHL) ubiquitin ligase. VHL
can also be inactivated via genetic mutation, genetic loss, or
epigenetic suppression, all events most commonly associated
with hereditary and sporadic clear cell renal cell carcinoma
(CCRCC)[24,25].HIFoverexpressioncorrelateswithhighly
vascularized tumors, resistance to chemo- and radiotherapy,
and overall poor prognosis [26] .T h ee s s e n t i a lr o l eo fH I Fi n
tumor angiogenesis has been functionally validated in many
models [27, 28], highlighting its importance and validity as a
clinical target.
Although no speciﬁc anti-HIF targeting strategies have
beenapproved,anumberofcurrentlyutilizedantiangiogenic
agentshavesuppressiveeﬀectsuponHIFactivityorsynthesis
and diminish HIF-mediated VEGF expression [19]. Several
of these agents exhibit antiangiogenic and antitumorigenic
eﬀects in preclinical models [29–32] and two speciﬁc HIF
inhibitors are being evaluated in Phase I trials, the small
molecule PX-478 [33], and the antisense oligonucleotide
EZN-2968 [34]. The use of Hsp90 inhibitors as a strategy to
target HIF emerged shortly after HIF was ﬁrst identiﬁed as
anHsp90 clientprotein [35].Manyoftheantivasculareﬀects
of Hsp90 inhibitors are likely due to the ability of this class of
inhibitors to downregulate HIF activity. We and others have
shown that both the HIF-1α and HIF-2α subunits are client
proteins for Hsp90 and that chaperone activity is required
for HIF stability and function [35–39]. Importantly, Hsp90
inhibitors, such as GA and its clinical derivative 17-AAG,
promote proteasomal degradation HIF-α in a PHD/VHL
and oxygen-independent manner, instead of utilizing the
ubiquitin ligase RACK1 [37, 40–42]. Thus, Hsp90 inhibitors
abrogate HIF signaling even in the absence of a functional
PHD/VHL system, suggesting that these pharmacological
agents may be able to dampen the constitutive HIF signaling
associated with most solid tumors. This notion is supported
by the ability of Hsp90 inhibitors to decrease VEGF secretion
from cancer cells, impair endothelial cell tubule formation
in vitro,a n dr e d u c ein vivo tumor size and vascularization
[43–45].
2.2. Hsp90 as an Eﬀector of VEGF Expression and Angiogenic
Activity. Although HIF is a main eﬀector of VEGF-mediated
signaling, HIF-independent proangiogenic processes also
contribute to increased VEGF-dependent proangiogenic
signaling[46].NFκBpotentlyinducestumorvascularization,
in part through its ability to upregulate VEGF expression
through an IL-8/NFκB signaling axis [47]( Figure 1). Secre-
tion of IL-8, a potent proangiogenic factor, is mediated
through a variety of mechanisms including other cytokines,
cellular stress, and hypoxia (Figure 1)[ 48]. A positive
feedback loop has also been reported whereby NFκBc a n
induce IL-8 and angiogenin secretion to promote tumor
neovascularization through the recruitment of bone mar-
row derived cells [49]. Blockade of NFκB signaling in an
orthotopic model of ovarian cancer inhibited tumor growth,
reduced tumor angiogenesis, and suppressed VEGF and IL-8
expression [50]. In addition to its role in HIF-independent
upregulation of VEGF, NFκB has also been shown to
transcriptionally induce the physiological expression of HIF-
1[ 51]; however, it is not known whether this pathway
may also exist in transformed cells. Although NFκB itself
is not a validated Hsp90 client protein, multiple directJournal of Oncology 3
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Figure 1: Hsp90-dependent modulation of proangiogenic signaling pathways in cancer. Hsp90 regulates multiple arms of angiogenic signaling
in cancer. Key signaling molecules that are either direct clients or indirectly modulated by Hsp90 are shaded in red. One pathway that is
commonly upregulated during tumorigenesis is the HIF/VEGF signaling axis. Tumor hypoxia and other stimuli induce HIF expression and
subsequent activity, leading to a cascade of events that reinforce VEGF expression and angiogenesis. Importantly, several key mediators
of this pathway, including HIF and VEGFR, are dependent upon Hsp90 for their function. As indicated, RTK activation also potently
upregulates HIF via AKT/mTOR -mediated translation. RTKs additionally transactivate EphA2, a recently identiﬁed Hsp90 client protein
known to participate in tumor vascularization. Providing another level of complexity, HIF also upregulates the expression of several RTK
ligands(e.g.,HGFandTGF-alpha),aswellasRTKreceptors(EGFR,IGFR),therebyreinforcingthesesignalingnetworks.Hsp90additionally
plays a role in NFκB-dependent VEGF expression and regulates downstream eﬀectors of VEGF signaling, including AKT-mediated eNOS
phosphorylation. Given the intertwining levels among Hsp90 and angiogenic signaling cascades, Hsp90 intervention is predicted to impair
signaling at many levels within these redundant pathways, with the overall eﬀect of suppressing tumor angiogenesis.
modulators of NFκB activation are subject to regulation by
Hsp90,permittingHsp90-inhibitor-mediated suppressionof
NFκB[ 52–55]. Moreover, NFκB may directly regulate Hsp90
expression through two binding sequences in the Hsp90
promoter, [56] suggesting the possibility of a feedback loop
whereby Hsp90 inhibition decreases NFκB activity, which
may further decrease Hsp90 levels. It remains to be seen
whether these HIF-independent angiogenic regulators of
VEGF are appropriately suppressed upon Hsp90 inhibitor
treatment in relevant preclinical models.
In addition to its involvement in both HIF and
NFκB mediated VEGF production, Hsp90 also modulates
downstream eﬀectors of VEGF-dependent signaling. VEGF
mediates many of its proangiogenic eﬀects through stim-
ulation of the enzyme endothelial nitric oxide synthase
(eNOS). In endothelial cells, activated eNOS leads to nitric
oxide (NO) synthesis and release [57], which in turn
promotes angiogenesis through endothelial cell proliferation
and migration, as well as having eﬀects on blood ﬂow
throughmodulationvasculartoneandpermeability[58,59].
Mechanistically, VEGF binds to and activates the VEGF-R2
receptor, promoting phosphorylation of associated Hsp90
[60].ThisphosphorylatedHsp90,inturn,servesasascaﬀold
to facilitate the association between eNOS and AKT, thereby
promoting AKT-dependent phosphorylation and activation
of eNOS (Figure 1)[ 61]. Microenvironmental factors such
as hypoxia may facilitate angiogenesis by increasing the
interaction between Hsp90 and eNOS concomitant with
increased AKT activity in endothelial cells [62]. The asso-
ciation between eNOS and Hsp90 can be further stabilized
by sphingosine-1-phosphate (S1P), a bioactive lipid induced
during hypoxia in an HIF-dependent manner [63, 64],
and reciprocally, S1P may stimulate HIF activity [65]a n d
elicit chemoresistance [66]. Given that VEGFR, AKT, eNOS,
and NFκB share a dependence upon Hsp90, [67, 68]
(Figure 1), Hsp90 inhibitors have the potential to target4 Journal of Oncology
multiple steps of this pathway, as demonstrated by the
potent suppression of VEGF and NO release both in vitro
[69, 70] and in preclinical models [71, 72]. Additionally,
17-AAG directly inhibits transcription of eNOS mRNA in
the in vitro angiogenic HUVEC (human umbilical vein
endothelial cells) model, although the mechanism remains
unknown [71]. Moreover, Hsp90 inhibitors decrease the
expression of activated AKT and eNOS in HUVEC cells,
concomitant with inhibitory eﬀects upon tubule formation
[72]. Therefore, the antiangiogenic properties of Hsp90
inhibitors are due in part to their ability to suppress HIF-
dependent and independent VEGF expression and dampen
the signaling potential of VEGF through modulation of
VEGFR,AKT,andeNOSfunction.Inlightofthesefunctions,
Hsp90 chemotherapeutics have the potential to potently
suppress tumor angiogenesis by attenuating the secretion
of cancer-derived angiogenic factors as well as by blocking
paracrine and autocrine signaling in the tumor-associated
endothelium.
2.3. Hitting Hard: Hsp90 Inhibition as a Multifaceted Strategy
to Combat Tumor Vascularity and Drug Resistance. Although
VEGF plays a pivotal role in tumor angiogenesis and VEGF-
targeted agents represent the cornerstone of many antian-
giogenic approaches in malignant disease, the majority of
these initially responsive tumors subsequently acquire drug
resistance [3]. Broadly speaking, antiangiogenic tyrosine
kinase inhibitors (TKIs) act by neutralizing VEGF/VEGFR
signaling, VEGFR in combination with other proangiogenic
RTKs, or target distinct RTKs that may not include VEGFR
[3, 73, 74]. Common among all TKI-initiated strategies is
a lack of durable response, an outcome that represents the
biggest clinical challenge with TKI therapy. This universal
property of therapeutic failure is a product of both de
novo resistance, due to the inherent genetic complexity and
heterogeneity of tumors, and to acquired resistance, a result
of the plasticity and signaling redundancy characteristic of
tumorcells[3,75–77].InthecaseoffailureofVEGF-targeted
therapy, the activation of compensatory mechanisms fosters
adaptation and independence from VEGF signaling [78].
Compensatory and redundant signaling is a characteristic
of several cancer types, such as glioblastoma multiforme
(GBM), wherein activation of PDGF, MET, and EGFR
family members collectively limits the therapeutic eﬃcacy
of speciﬁc TKI agents [79]. Importantly, the ability of
angiogenic cytokines to activate their cognate RTK receptors
is also a major determinant in conferring chemoresistance.
Therefore, the salient ﬁnding that RTKs comprise the largest
category of Hsp90 client proteins [7, 68, 80]( Figure 1)h o l d s
clinical promise for the ability of Hsp90-directed agents
to suppress angiogenic signaling and overcome therapeutic
resistance in diverse cancers. The following section will
discuss Hsp90-modulated eﬀectors of RTK driven angiogen-
esis, highlight several redundant signaling mechanisms con-
tributing to drug resistance, and outline prospects for Hsp90
intervention and opportunities for reversal of this resistance.
The PDGF-FGF-VEGF signaling module represents a
highly integrated pathway commonly activated in a num-
ber of cancers. The PDGF-α receptor participates in cell
transformation, regulation of vascular permeability, and
VEGF expression [81, 82]. Highlighting the complexity
and interconnectedness of angiogenic signaling, PDGF also
synergizes with FGF to stimulate neovascularization [83]
and FGF, in turn, cooperates with VEGF to stimulate
blood vessel maturation and function [84]. Clinically, several
antiangiogenic TKIs are currently approved as inhibitors for
these growth factor/RTK pairs, such as imatinib mesylate
(gleevec),sorafenib,andothers[85].Theinterconnectedness
of these pathways suggests a potential beneﬁt of combining
TKIs in antiangiogenic therapy, supported by the clinical
observation that combination of a pan-VEGFR inhibitor
(sunitinib) with a PDGF inhibitor (AGO13736) delayed
tumor progression more eﬀectively in cytokine refrac-
tory renal cancer [86]. The EGF-IGF-HGF-VEGF signaling
module represents another proangiogenic molecular hub.
ActivationoftheMETRTKreceptorbyitsligand,hepatocyte
growth factor (HGF), which may be upregulated by a HIF-
dependent pathway [87], has pleiotropic angiogenic eﬀects
including upregulation of VEGF and its receptor [88], as
well as stimulation of HIF-mediated VEGF secretion [89].
MET also cooperates with epidermal growth factor receptor
(EGFR) through the downstream eﬀectors PI3K/AKT [77].
EGFR family members EGFR and HER2 are overexpressed
in many cancers and are integral to tumor progression, in
part due to their ability to stimulate release of angiogenic
factors including VEGF [90]. Continuing the theme of cross-
communication, EGFR and HER2 cooperate with IGFR
through the PI3K pathway to synergistically increase vessel
growth[91].AlthoughcancercellsharboringampliﬁedMET
are initially sensitive to MET TKIs in vitro, they evade this
inhibition, despite durable MET inhibition, via reactivation
of EGFR and downstream mediators [92]. Antiangiogenic
TKIs targeting these receptors are being evaluated in Phase
I and II clinical trials [3].
The targeting of EGFR with geﬁtinib provides a well-
characterized scenario illustrating the pleiotropic mecha-
nisms at play in drug evasion. One common mechanism
for therapeutic escape is conferred by secondary mutations
in RTKs that impair the ability of targeted therapeutics
to recognize and block receptor function. For example,
although at least three EGFR TKIs are in clinical trials
(imatinib, geﬁtinib, and erlotinib), resistance occurs with
a frequency of 70% in lung cancer patients, due to the
acquisition of secondary mutations in the kinase domain
[76, 93]. Another caveat is that geﬁtinib treatment results
in the activation of signaling pathways that collectively serve
to limit its antitumor activity and allow acquired resistance
to emerge. A number of these resistance mechanisms have
been identiﬁed in both preclinical and clinical studies and
include activation of oncogenic signaling, HGF, VEGF,
and PI3K/AKT activation, the latter of which plays a role
in de novo resistance and sustenance of EGFR activation
i nan u m b e ro fc a n c e r s[ 77, 85, 94–98]. A number of
studies implicate the contribution of IGF-1R and FGFR
as participants in both intrinsic and acquired resistance
to EGFR TKIs [98]. These ﬁndings strongly advocate the
use of combination therapy as a means to overcome this
signaling redundancy and subsequent drug resistance. InJournal of Oncology 5
support of this notion, it was demonstrated that coad-
ministration of geﬁtinib and an IGF-1R inhibitor (NVP-
AEW541) in a geﬁtinib resistant xenograft model reversed
drug resistance [99]. Other reports also document the
importance of cotargeting downstream molecules, including
the Hsp90 regulated eﬀectors PI3K/mTOR and MEK, in
regaining drug responsiveness in EGFR mutant cancers [98].
These examples highlight the large scope of compensatory
mechanisms utilized by tumor cells and the need for broad
acting agents and/or combinatorial approaches such as those
represented by Hsp90-directed chemotherapeutics.
TheinherentabilityofHsp90-targetedagentstosuppress
multipleproangiogenicreceptorsandeﬀectorproteinsbodes
well for their prospects in overcoming the redundancy of
signaling required for adaptive responses. In support of this
premise, geldanamycins (GAs) destabilize MET, inhibit its
angiogenicfunction[100],andsuppresscoordinatesignaling
eﬀectorsthateludereceptor-speciﬁctargetingstrategies[92].
Blocking Hsp90 also inhibits IGFR and PDGFR function
and reduces their angiogenic potential in vivo [45, 101].
Similarly, GAs suppress EGFR/HER2 signaling, impair mul-
tiple pathways associated with receptor upregulation, and
reduce tumor growth and vascularization in vivo [45, 102,
103]. Importantly, TKI resistant EGFR mutant receptors
are exquisitely sensitive to Hsp90 inhibitors and these
agents synergize with EGFR inhibitors [104]. Interestingly,
clinical administration of 17-AAG led to tumor regression
in HER-2 positive metastatic breast cancer patients [105],
demonstrating the oncogene-addicted nature of this tumor.
The basis for the poor response in HER-2 negative subtypes
remainsunknown,giventhatHsp90inhibitionalsocotargets
pivotal downstream eﬀectors of RTK signaling, such as FAK,
MAPK, and AKT [67, 106, 107], which would be expected
to amplify their suppressive eﬀects and thwart adaptive
responses. This ability of Hsp90 inhibition to fundamentally
alter network circuitry in tumor cells bodes well for their
ability to potentiate the eﬃcacy of targeted or cytotoxic
drugs administered in tandem, a notion supported by its
synergistic antitumor and antivascular in numerous in vitro
and preclinical models [104, 108–112].
3. EphA2 Receptor as a Conduitfor RTK
ActivationandaDriverofAngiogenesis
The Eph RTK superfamily is of recent interest in relation to
proangiogenic proteins targeted by Hsp90-directed therapy.
Severalofthe16EphRTKsdemonstratefunctionspertaining
to vessel development during embryogenesis and in cancer
[113]. In particular, the EphA2 receptor is emerging as a piv-
otalregulatorofphysiologicalandpathologicalangiogenesis.
EphA2 plays an essential role in developmental angiogenesis,
as null endothelial cells fail to undergo cell migration and
vascular assembly both in vitro and in vivo [114]. A deﬁnitive
role for EphA2 in malignancy is illustrated by diminished
tumor growth, angiogenesis, and metastasis in EphA2 deﬁ-
cientmice [115].Furthermore,EphA2iscommonlydetected
in the tumor associated vasculature, where it facilitates
angiogenesis[116–118].EphA2isoverexpressedinanumber
of human malignancies, particularly in highly vascular
GBM tumors, where it serves as a prognostic factor [119].
Unlike most other ligand/RTK interactions, the association
ofephrinA1ligandwiththeEphA2receptorisinhibitory,due
to subsequent internalization and proteasomal degradation
of the receptor [113, 120]. In cancers, ligand expression is
downregulated during the malignant process [119], leading
to constitutive EphA2 signaling. In terms of therapeutic
options, no clinical TKIs against EphA2 have yet been
developed, nor have any already approved clinical agents
been shown to target EphA2. However, targeting of EphA2
signaling by either siRNA-mediated suppression of receptor
expression [121] or administration of a selective antibody
[122] are approaches that have demonstrated eﬃcacy in
preclinical models. Highlighting an alternative therapeutic
approach, we found that EphA2 receptor activity requires
Hsp90 function [123] and, further, that Hsp90-targeting
agents interfere with EphA2-mediated signaling and pro-
mote receptor destabilization. Therefore, Hsp90 inhibition
may represent a therapeutic approach to neutralize receptor
function and reduce the aggressiveness of EphA2-driven
cancers.
In keeping with the theme of cross-communication,
EphA2 is earning its place as an essential member of
an expanding network of protumorigenic eﬀectors. First,
EGFR activation drives MAPK signaling, which leads to
its upregulation in a number of aggressive cancers [124].
Secondly, EGFR family members co-opt EphA2 to promote
cell motility and proliferation [115, 125]. Third, EphA2 also
cooperates with VEGFR, as demonstrated by its requirement
for VEGF-induced endothelial cell migration and tubule
formation [126]. Finally, EphA2 function is transduced by
its ability to complex with AKT, the latter of which is
activated by diverse RTK ligands (EGF, FGF, HGF, and
PDGF) [120]. This multifaceted mechanism for EphA2
activation reinforces the theme of the previous section in
that the eﬀective blockade of EphA2 signaling will require
the simultaneous cotargeting of multiple RTKs. Growth
factor-mediated AKT phosphorylation in turn leads to
AKT-dependent EphA2 phosphorylation, which facilitates
EphA2/AKT complex formation (Figure 1). Formation of
this signaling unit is critical for tumor cell migration and
invasiveness. Although it remains unclear how this pathway
mechanistically translates to angiogenic potential, AKT is a
known mediator of angiogenic processes [127]a n dA K T -
mediated EphA2 phosphorylation within GBM-associated
tumor vasculature increases with malignancy [120]. Given
that AKT is a validated Hsp90 target protein [128]a c t i v a t e d
in a number of malignancies, and that AKT acts as a con-
duit for EphA2 signaling, Hsp90-targeting strategies should
be eﬀective in blocking EphA2/AKT-dependent angiogen-
esis. Interestingly, most of the aforementioned angiogenic
cytokines are also reported to stimulate VEGF secretion,
due in part to their ability to stimulate HIF translation
v i am T O R ,ad o w n s t r e a me ﬀector for AKT. As recently
reviewed [19], many of the aforementioned TKIs also down-
regulate HIF translation. Collectively, cytokine-mediated
activation of RTKs, and subsequently of AKT, stimulates HIF
translation, thereby potentiating VEGF-dependent signaling
and sustained angiogenesis (Figure 1). In a recent twist,6 Journal of Oncology
it was shown that HIF-2 regulates both the expression
and activation of multiple RTKs [129]. Furthermore, the
suppression of HIF dramatically improves tumor responses
to Sunitinib in colon cancer cells and strikingly prolonged
complete responses in half of the tumor bearing mice [130].
This demonstrated ability of HIF to regulate RTK signaling
and potentiate the eﬀects of antivascular agents further
emphasizes the complexity and cross-pollination of these
signaling pathways and supports the rationale for utilizing
Hsp90-targeted agents as a strategy to cotarget HIF proteins
and proangiogenic RTKs.
4. MurkyWaters:ClinicalChallenges of
Hsp90 Inhibition
Although Hsp90 sustains a multitude of angiogenic pro-
cesses critical for cancer progression, and Hsp90-targeted
agents demonstrate favorable responses across multiple
cancers in preclinical models, they have fared less well
in the clinic. Recent clinical failures include the use of
17-AAG in advanced prostate cancer and CCRCC [131,
132], the latter a particularly surprising outcome given
the putative HIF-dependent and angiogenic nature of this
tumor. However, these patients had already presented with
advanced metastatic disease, and it is therefore unclear
whether improved responses might have been observed with
earlier intervention. This section will evaluate some of the
more complex issues and potential pitfalls that may oﬀer
insight into the variable clinical response of these inhibitors,
including pharmacologic considerations,undesired eﬀectsof
Hsp90-directed therapy, and role of the tumor microenvi-
ronment.
4.1.Toxicity,Metabolism,andDelivery. Discordancebetween
Hsp90-targeted eﬃcacy in preclinical models compared
with less favorable clinical outcomes may be due to a
number of pharmacologic factors, independent of the ability
of these agents to target the appropriate protumorigenic
pathways. One issue may pertain to drug formulation,
as 17-AAG/Tanespimycin is a substrate for the multidrug
resistance(MDR)transporterP-glycoprotein,andtherelated
MRP eﬄux pump [133]. Acquired resistance of cells via
this mechanism has been observed in cell culture [134].
Another caveat is that drug potency requires reduction by
NAD(P)H:Quinone Oxidoreductase I (NQO1) [133, 135,
136];yetinformationislackingonNQO1expressionproﬁles
in treated patients. A new generation of purine-based Hsp90
inhibitors was subsequently developed [137] whose activity
does not depend upon this reduction event [134]. Purine-
based compounds are currently at the forefront of Hsp90
inhibitor advancement with several derivatives exhibiting
increased potency and decreased toxicity when compared to
17-AAG [138]. Furthermore, these agents are not subject
to metabolism by NQO1/DT-diaphorase enzymes nor to
eﬄux by P-glycoprotein, and tumor cells in culture that have
acquired resistance to 17-AAG remain susceptible to these
newer agents [134, 139]. Therefore, despite disappointing
earlyclinicalresultswith17-AAG,clinicalenthusiasmforthe
next generation of Hsp90 inhibitors remains high.
4.2. Molecular Caveats of Hsp90 Inhibition. In addition to
drug formulation challenges, inhibition of cellular Hsp90
initiates a heat shock response [140] that triggers activation
of heat shock factor 1 (HSF-1) [140] and corresponding
upregulation of prosurvival chaperones Hsp27, Hsp70, and
Hsp90.Thisheatshockresponseantagonizesdrugpotencyin
vitro and in vivo [140–143]. Furthermore, HSF-1 expression
is essential in supporting malignant transformation [144].
A heat shock response is similarly initiated with the newer
purine derivatives [139, 142] and therefore represents a
characteristic associated with this general class of Hsp90
targeting agents. However, it may be possible to address this
undesired eﬀectthroughcombination treatments. Forexam-
ple, cisplatin suppresses 17-AAG-mediated HSF-1 activation
and synergistically promotes tumor cell death in vitro [145].
ItremainstobeseenwhetherclinicalmodulationoftheHSF-
1-mediated heat shock response may enhance the clinical
eﬃcacy of Hsp90-directed therapy.
Another less well-understood consideration involves
molecular factors that may alter the eﬃciency of Hsp90-
mediated client destabilization. Many Hsp90 client proteins
are destabilized via the concerted action of ubiquitin ligases
and the proteasomal pathway; however little is known about
the molecular eﬀectors involved in client destabilization
following Hsp90 inhibition. Taking HIF as an example, we
have previously demonstrated that the association of HIF
with its dimerization partner ARNT promotes dissociation
of Hsp90 from HIF, with resultant protection from Hsp90
inhibiting agents [40]. Since that report, others have doc-
umented additional HIF binding or accessory proteins that
may share a similar propensity to modulate the eﬃciency
of Hsp90 directed HIF degradation [42, 146, 147], high-
lighting the previously unappreciated molecular complexity
associated with Hsp90-targeted therapy. Recently, a group
demonstrated that expression of Cullin5, a ubiquitin ligase,
was required for optimal degradation of HIF and ErbB2
[148]. Importantly, Cullin5 expression is decreased in an
overwhelming majority of breast cancers [149], suggesting
that tumor cells may acquire the ability to evade or limit the
destabilization eﬀects of Hsp90-dependent chemotherapy
upon subsets of clients. The identiﬁcation of these modiﬁers
and an analysis of their expression in human cancers may
be required to gauge the clinical potential of Hsp90-directed
therapy against speciﬁc clients or signaling pathways.
4.3. Fighting a Tiger: Contribution of Stroma to Tumor
Angiogenesis and Malignant Progression. Another factor in
the disconnect between preclinical results and eﬃcacy in
patients is likely attributed to the inﬂuence of the tumor-
adjacent stromal tissue. The tumor stroma, which inﬂuences
the microenvironment surrounding the neoplastic lesion, is
a driving force of both tumor growth and vascularization.
This heterogenous stroma is comprised of a variety of cell
types, including ﬁbroblasts/myoﬁbroblasts, smooth muscle
cells and endothelial cells, immune cells, and bone marrow
progenitor cells (Figure 2)[ 150], all of which collaborate
to spur tumor growth. Clinically, an abundant fraction of
the tumor reactive stroma is composed of cancer-associated
ﬁbroblasts (CAFs), or myoﬁbroblasts, whose presence isJournal of Oncology 7
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Figure 2: Potential for Hsp90 intervention strategies in curtailing angiogenic processes. Tumor stromal cells, such as cancer-associated
ﬁbroblasts (CAFs) and endothelial cells (ECs), communicate with tumor cells via their secretion of cytokines and thus contribute to the
angiogenic switch (1). Cytokines from recruited BMDC progenitors contribute to this milieu to further stimulate tumor vascularization
(1). Hsp90 inhibition may prevent HIF-driven cytokine release from tumor and stromal cells (i.e., SDF-1, VEGF, HGF, etc.), as well as
HIF-mediated CXCR4+ expression in BMDCs, with the potential eﬀect of curtailing recruitment of CXCR4+ progenitors to the tumor.
Hsp90 inhibition also attenuates cytokine signaling via RTK inhibition (i.e., VEGFR, PDGFR), which may collectively prevent or delay the
angiogenicswitch.Therapeuticapproachesutilizingradiotherapy(RT),tyrosinekinaseinhibitors(TKIs),orHsp90-targetedagentssuppress
tumor vascularization and growth (2). This initial reduction in vascularity may promote tumor hypoxia (3), subsequent HIF activation, and
SDF-1 secretion, the latter of which may further stimulate BMDC recruitment (4). Hsp90 inhibitors are similarly predicted to suppress
BMDC recruitment and HIF-driven cytokine secretion as in (1). Alternatively, when challenged with reduced HIF expression and decreased
BMDCrecruitment,tumorcellsmaycooptthevasculatureofnormaltissue(5).Inthisscenario,Hsp90suppressionispredictedtoreducethe
eﬃciency of EC-derived factors that support this process. The overall eﬃcacy of Hsp90 inhibition upon tumor vascularization will depend
upon the balance of Hsp90-dependent and Hsp90-independent signaling eﬀectors driving the angiogenic process.
recognized as a risk factor for neoplastic transformation.
This tumor supporting function is due to their ability to
upregulate ECM proteins and secrete growth factors and
cytokines, (i.e., ﬁbroblast growth factor (FGF), connective
tissue growth factor (CTGF), stromal-derived factor (SDF-
1) and VEGF), thereby creating conditions that constitute
an optimal milieu for tumor development [151, 152].
CAFs robustly stimulate tumor angiogenesis and cancer
progression in a number of xenograft models [153–157].
Myoﬁbroblasts are also a component of nontumorigenic
ﬁbrotic tissue, such as in gastric, pancreatic, and hepatic
stellatecells,whichsimilarlysecreteangiogeniccytokinesand
support paracrine signaling in adjacent epithelial cells [158].
Hypoxic signaling further drives ﬁbrogenesis [159], and the
hypoxia-mediated upregulation of VEGF and angiogenic
cytokines from stellate cells perpetuates the ﬁbrotic and
hypoxic cycle [158, 160].
Given that myoﬁbrolasts support and sustain cancer
progression, there is heightened interest in agents that
may target the CAF-rich stroma [161]. Although Hsp90-
targeted strategies are predicted to interfere with the VEGFR,
PDGFR, and TGF beta receptor signaling that participates
in tumor-stromal communication, reports examining the
ability of either TKIs or Hsp90 inhibitors to attenuate
CAF/stellate signaling are limited. Multi-TKIs reverse prop-
erties associated with the activated stellate phenotype in
vitro and in vivo [162, 163], concomitant with reduced
tumor vascularity [164], and Imatinib inhibits PDGF/AKT
signaling and ECM production in breast stromal ﬁbroblasts
[165]. Hsp90 inhibitors exhibit cytotoxicity against CAFs
derived from gastric cancer [44], which are potent mediators
of tumor angiogenesis [166]. Interestingly, Hsp90 inhibition
suppresses the reactive stromal phenotype in hepatic stellate
cells, prior to initiating apoptosis [167], suggesting that
Hsp90-targeted agents may be eﬀective in reducing stromal
support of tumorigenic progression.
Given that CAFs promote tumor vascularization in
part via their ability to stimulate endothelial cell function,8 Journal of Oncology
attentionhasnowshiftedtotheabilityofTKIstocotargetthe
tumor endothelium. The stromal vasculature is comprised
of endothelial cells and perivascular pericytes, the latter of
which provide both survival signals and structural support
to facilitate a mature and functional vasculature [168]. The
pathways crucial to EC-pericyte communication and vascu-
lar stabilization include PDGF/PDGFR and VEGF/VEGFR
signaling. Secretion of PDGF from cancer cells stimulates
VEGF upregulation in pericytes via a PI3K/AKT mechanism,
which protects ECs from apoptosis [169]. Furthermore,
PDGF signaling is essential for tumor vascularization in a
preclinical model of pancreatic cancer [170] and upregulated
PDGF signaling is a characteristic of the tumor stroma in
a preclinical model of cervical cancer [171]. In the latter
example, expression of the PDGF receptor was primarily
localized to stromal ﬁbroblasts and pericytes, and inhibition
of PDGFR signaling with Imatinib decreased pericyte cover-
age of tumor endothelial cells, concomitant with suppression
of tumor vascularity and growth.
Hsp90 inhibitors are well characterized in their ability to
suppress tumor vasculature and growth in multiple preclin-
ical models; yet their speciﬁc eﬀects upon endothelial cells
and pericytes remain largely unexplored. A limited number
of reports demonstrate that Hsp90 inhibition reduces pro-
liferation, diﬀerentiation, motility, and angiogenic signaling
in normal human endothelial cells [72, 139] and may elicit
deathofnormalvascularsmoothmusclecells(representative
of pericytes) at high concentrations [44], but the molecular
mechanisms for these eﬀects remain obscure. The precise
molecular eﬀects of Hsp90 inhibition within the tumor-
associatedvasculaturehavenotbeenclariﬁed,anduseofnor-
mal cells that resemble components of the tumor vasculature
may not accurately reﬂect the tumor endothelium. Further,
Hsp90 inhibitors may diﬀerentially destabilize proteins in
tumor and vascular cells [101], illustrating the potential for
diﬀerential tumor and stromal responses to therapeutics.
Importantly, Hsp90 therapeutics may exhibit preferential
uptake and selectivity for tumor tissue, proportional to
the cancer speciﬁc hyperactivity of the Hsp90 chaperone
[172, 173], inviting the question of whether these agents will
eﬀectively target components of the nontumorigenic stroma.
4.4. The Tumor Stroma as an Enabler of Therapeutic Resis-
tance. Clinically, chemoresistance may be due to a failure
to target the proangiogenic signaling derived from tumor
stroma, a notion supported by the ability of CAFs to mediate
drug sensitivity [174, 175]. Endothelial cells also contribute
to chemoresistance, as demonstrated by the use of temo-
zolomide in the treatment glioblastoma multiforme (GBM).
While temozolomide exhibits toxicity against GBM cells in
culture, glioma-derived endothelial cells are refractory to
treatment,thusoﬀeringapossibleexplanationfortheclinical
failure of these agents [176]. Similarly, the ability of pericytes
to protect against EC apoptosis [169] implicates their poten-
tial role in attenuating the eﬃcacy of chemotherapeutics.
In support of this notion, dual inhibition of PDGFR and
VEGFR signaling is synergistic in reducing pericyte coverage
of tumor endothelium, and this combination is maximally
eﬀectiveinsuppressingtumorgrowthovereitheragentalone
inamousemodelofpancreaticisletcancer[177].Inaddition
to its role in chemoresistance, the tumor stroma also plays
a major role in mediating the response to radiotherapy
(RT). It is established that RT induces the expression and
secretion of VEGF and proangiogenic cytokines in cancer
cells, stromal endothelial cells, and ﬁbroblasts [178–180].
This cytokine upregulation stimulated by the initiation of
vascular repair mechanisms and HIF-dependent signaling
[181, 182] represents a major barrier to chemosensitivity
[183–185].
Antiangiogenic TKIs have met with limited success
in combating radioresistance, despite their impairment of
proangiogenicRTKsignalinginbothtumorandstromalcells
[186]. Although not yet validated clinically, we, and others,
have shown that Hsp90 inhibition imparts radiosensitivity
to various cancer cell types in culture and in vivo [187–189].
While the basis for this enhancement is not well deﬁned,
Hsp90-dependent HIF targeting is one likely mechanism,
supported by the ﬁnding that blockade of HIF/VEGF signal-
ing, coupled with RT, potently destroys tumor vasculature in
ax e n o g r a f tm o d e l[ 190]. In further support of the ability
of Hsp90 inhibition to impair this signaling axis, Hsp90-
directed therapy overrides the protective eﬀects of VEGF-
mediated signaling in endothelial cells, in part through
inhibition of AKT [191]. Since many of the RT-induced
wound repair response pathways depend upon a number of
Hsp90 clients, including HIF, AKT, MEK/ERK, PDGFR, and
VEGFR, Hsp90 inhibition represents an alternate approach
to impair multiple radioresponse regulatory proteins and
improve outcome. In fact, it remains a possible, though
unconﬁrmed notion, that the ability of Hsp90 inhibitors
to destabilize interactions between ECs and pericytes may
underlie their ability to suppress tumor vascularity and
potentiate chemo- and radiosensitivity. However, given that
optimal responses to the combination of anti-VEGF therapy
with RT occur during the “normalization window” charac-
terized by stabilization of the tumor vasculature subsequent
to enhanced pericyte coverage [192], the use of Hsp90
inhibitors will have to be judiciously applied for optimal
therapeutic beneﬁt.
Similar to RT, vascular targeting agents exacerbate tumor
hypoxia and activate HIF signaling, events antagonistic to
treatment objectives. HIF activation stimulates cytokine
secretion and recruitment of circulating BMDCs (Figure 2),
which may replenish vascular components such as peri-
cytes, CAFs, and myeloid cells. Mobilization of BMDCs to
hypoxic areas promotes neovascularization and contributes
to cancer aggressiveness and drug resistance [2, 193, 194].
Although factors regulating BMDC recruitment are not well
deﬁned, tumor hypoxia and the HIF-regulated cytokines
VEGF and SDF-1 are established as major eﬀectors in the
recruitment of VEGFR and CXCR4 expressing BMDCs [49,
195, 196]( Figure 2). In a well-validated preclinical model,
hypoxic or irradiated glioma cells each secreted factors
that stimulated the homing of hematopoietic progenitors
in a HIF-dependent manner [197]. The enhancement of
tumor hypoxia via genetic or pharmacologic interference
with VEGF signaling similarly recruited BMDCs and fueled
aggressiveness [198, 199]( Figure 2). It remains to be seenJournal of Oncology 9
whether Hsp90-directed therapy may eﬀectively suppress
HIF-mediated recruitment of BMDCs and whether attenu-
ated recruitment may be suﬃcient for tumor suppression.
Indeed, BMDC recruitment was diminished in a HIF-1
knockout mouse model of glioma; yet tumor cells became
invasive and continued to thrive via cooption of the host
vasculature [200]. In this example, the host cells were
still competent to respond to tumor-mediated HIF/VEGF
signaling, leaving open the possibility that Hsp90 inhibition,
which would target HIF signaling in conjunction with VEGF
mediated responses, may thwart this undesired adaptive
event (Figure 2).
Another level of complexity is due to the nature of
angiogenic compensation, in that HIF-independent com-
pensatory mechanisms, such as NFκB-dependent cytokine
release, can also promote BMDC recruitment [49]. Hsp90
inhibitors have the potential to impair a subset of HIF-
independent mechanisms, for example, by virtue of their
ability to suppress eﬀectors such as NFκB. Although the role
of Hsp90-dependent signaling within the context of BMDC-
mediated neovascularization has not been explored, the
ability of Hsp90 inhibitors to suppress BMDC stimulatory
propertiesuponmultiple myelomacellsinacoculturemodel
[72] suggests that these agents may indeed have utility in
preventing some aspects of BMDC-derived neovasculariza-
tion. However, these agents are likely to incur a number
limitations, given the recent identiﬁcation of a subset of
myeloidcellsthatarerefractorytoVEGF-dependenttherapy,
due to expression of G-CSF and Bv8, the latter of which
drives local angiogenesis, as well as BMDC recruitment [199,
201]. As these ligands activate G-coupled protein receptors
(GPCRs) that may not rely upon Hsp90 function, it is
possible that this alternative angiogenic pathway will be
immune to Hsp90-directed therapy. It therefore remains to
be determined whether the lack of durable clinical response
of Hsp90-directed therapy is due to an inability to suppress
BMDC recruitment, to inhibit vascular cooption, or to
suppress these compensatory angiogenic pathways. A further
characterization of these pathways may pave the way to
more successful regimens that employ rationally designed
combination therapies.
4.5. The Road to Nirvana: Improving Preclinical Models,
Drug Analyses, and Clinical Correlates. With the overarching
goal of understanding the basis for clinical responses to
Hsp90-targeted therapy, a continuum of models must be
evaluated, each with its inherent strengths and weaknesses.
Althoughcell-basedinvitromodelsarenecessarytodecipher
deﬁned molecular signaling events, these systems do not
recapitulate the complexity of the tumor microenvironment,
such as dimensionality, matrix incorporation, or stromal
communication, all factors that inﬂuence antiangiogenic
responses [202, 203]. Xenograft models, which embody
much of the complexity of the tumor microenvironment,
are a necessary prerequisite for evaluating the utility of
antiangiogenic agents in distinct cancers. However, the
majority of these models utilize immunocompromised mice,
which lack the full complement of immune components that
may contribute to stromal dependent angiogenesis. Some of
these diﬀerences invariably account for the ability of Hsp90
inhibitors, and other chemotherapeutics, to exhibit more
potent tumor eﬃcacy in preclinical models compared with
their clinical responses. Immune competent genetic models
ofprogressive cancerthatmore closelymimic the complexity
of human malignancy represent valuable tools for dissection
of stepwise genetic events in this process and may also
help pinpoint when antiangiogenic agents would be most
eﬃcacious.
Another caveat to deciphering optimal treatment regi-
mens is imparted by the molecular heterogeneity of cancers.
Functionally, this is exempliﬁed by the diﬀerential wiring
of signaling networks, and the corresponding diﬀerential
response to Hsp90 inhibition, a trait similarly reﬂected with
other chemotherapeutics. These varying responses likely
reﬂect the distinct molecular signatures driving cancer sur-
vival, each with a unique dependence upon Hsp90 function
[204], combined with disparate local microenvironments
from the periphery to the core. Moreover, diﬀerential client
aﬃnity in diverse cell and cancer types [205] hints at more
complex molecular regulation. Further, the recent revelation
that an average human tumor may have upwards of 20,000
mutations[206,207]stronglysupportstherationaleforther-
apeutic strategies incorporating more broadly acting drugs,
such as those represented by the category of Hsp90-directed
agents. In addition to tumor cell heterogeneity, components
of the tumor vasculature may demonstrate comparable
complexity. In support of this notion, VEGF resistant
CAFs may upregulate PDGF signaling [175]a n dp r o m o t e
chemoresistance. Similarly, the tumor endothelium exhibits
signiﬁcant heterogeneity of expressed surface molecules,
as validated with use of phage display technology, based
upon the principle of diﬀerential homing of peptides to the
vasculature [208–210]. Interestingly, this approach identiﬁed
distinct molecular signatures of the tumor endothelium that
occur in a stage speciﬁc manner, with clinical implications
for the variable tumor responses observed for TKIs. In
a preclinical model of cervical cancer, a subset of TKI
agents demonstrated preferential activity at distinct tumor
stages, implicating their selective eﬀects upon either tumor
initiationorsignalingeventsactivatedatlaterstages[171].In
thismodel,combinationtreatments(i.e.,cotargetingVEGFR
and PDGFR) demonstrated improved antitumor activity
of progressive tumors, illuminating that optimal targeting
approaches may need to consider prevention and inter-
vention strategies as a component of the heterogeneity of
thetumor-associatedvasculature.Similardynamictreatment
analysesinwell-deﬁnedpreclinicalmodelswillfurtherdeﬁne
optimal clinical usage for Hsp90 inhibitors.
In addition to allowing a dynamic evaluation of drug
eﬃcacy, preclinical models are useful tools to assess complex
drug-dependent molecular changes. A subset of microRNAs
was recently identiﬁed as components of the angiogenic
switch in a genetic model of pancreatic cancer. Strikingly,
these same targets were similarly upregulated in patients and
modulated preclinically following treatment with Sunitinib
[211]. Although a comparative detailed genetic analysis has
not yet been performed with Hsp90 inhibitors, one group
evaluated pharmacodynamic markers and resultant tumor10 Journal of Oncology
angiogenesis [139], while another performed a proteomic
and genetic analysis to identify a number of gene and protein
changes [212]. Further preclinical models that incorporate
dynamic molecular analyses have great potential for eval-
uating the eﬀects of emerging Hsp90 inhibitors. Similarly,
clinical trial design is likely to beneﬁt from the incorporation
of increasingly sophisticated molecular endpoints. Although
the evaluation of changes in tumor burden and disease
progression are established components of the clinical
evaluation of anticancer agents, according to the RECIST
(response evaluation criteria in solid tumors) criteria [213],
these endpoints may not be optimal in obtaining nuanced
information about tumor responses and changes within
the tumor microenvironment. For example, in trials with
Hsp90-targetedagents,apertinentendpointwouldentailthe
monitoring of drug-dependent depletion of relevant cancer-
causing client proteins. In a recent Phase II trial of 17-AAG
in melanoma, diﬀerential drug responses were observed for
client proteins from patient tumors [214], which may have
implications for clinical outcome. Therefore, the ability to
dynamically image Hsp90-dependent client depletion in vivo
would be a clinically valuable addition to these trials. At
least two reports demonstrate the feasibility of noninvasively
viewing the dynamic expression of Hsp90 client proteins in
real time in preclinical models [215, 216], suggesting that
incorporation of these approaches into clinical trial design
may be feasible.
More recently, a number of clinical trials have included
increasingly sophisticated molecular endpoints to gauge
drug responses. In a phase II trial of 17-AAG in metastatic
prostate cancer, the relation between drug treatment and
P S Aw a sm o n i t o r e d ,a sw e r eal i m i t e dn u m b e ro fs e r u m
derived cytokines and markers from peripheral blood [131].
In a carefully designed trial of a pan-VEGF inhibitor in
GBM,MRIimagingoftumorvascularitydiscernedawindow
of vascular normalization [217]. Importantly, this group
also identiﬁed several vascular modulators that correlated
with tumor progression, such as circulating endothelial
cells (CECs) and a subset of cytokines, such as SDF-1.
In another detailed study by this group, a comprehensive
genetic analysis of angiogenic markers revealed that anti-
VEGF therapy induced SDF-1 and inﬂammatory pathways
in rectal cancer [218]. This integrative analysis of stage
speciﬁc molecular and genetic alterations, coupled with the
evaluation of surrogate biomarkers, represents a promising
approach to better understand and possibly predict ﬂuctua-
tions in the clinical response to Hsp90 inhibitors. Looking
forward, it must be determined whether and how Hsp90
inhibitorsmodulatesignaling,angiogenicgenes/microRNAs,
cytokines,circulatingendothelialandprogenitorcells,tumor
stroma, and which of these alterations are prognostic for
tumor response or relapse. Whether the expanded repertoire
of proteins targeted by Hsp90 inhibitors, compared with the
relatively speciﬁc subset of proteins targeted by clinically
approvedantiangiogenicTKIs,willbeanassetoraliabilityin
the clinic remains to be determined. A more comprehensive
understanding of the mode of action of Hsp90 inhibitors will
position us to harness the power of these agents and design
more eﬀective strategies to diminish cancer lethality.
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